Showing 2601-2610 of 8635 results for "".
Recognizing Dermatologic Emergencies in Kids
https://practicaldermatology.com/conferences/scale-2023/recognizing-dermatologic-emergencies-in-kids/20198/Infections including congenital infections, syphilis, or HSV are the No. 1 cause of pediatric skin emergencies. Infantile hemangiomas in the airway can affect breathing and also require fast and early treatment, explains Thy Huynh, MD.Of Sharks and Sunscreen
https://practicaldermatology.com/series/scientifically-speaking/of-sharks-and-sunscreen/20130/Often called on to judge "Shark Tank"-style competitions, Humberto Antunes has an eye for what makes an idea work. He talks with host Joel L. Cohen, MD about ingredients for success and also offers insight on sunscreen access in the US.DermWireTV: USPSTF Tackles Racism; Winlevi Launch; Derm Days in Focus
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-uspstf-tackles-racism-winlevi-launch-derm-days-in-focus/20014/The US Preventive Services Task Force is undertaking efforts to mitigate the influence of systemic racism in its recommendations. Global Psoriasis Day, National Biologics Coordinators Day, and Retinol Day bring attention to skin issues. Sun Pharmaceutical’s Winlevi (clascoterone) cream 1% is now avaStay Relevant with Education
https://practicaldermatology.com/series/dermatology-education-foundation/stay-relevant-with-education/19989/Feed yourself new information and stay on top of data regarding new and existing medications in order to offer patients the best care possible, says Wendy Cantrell, CRNP, DNP. This is particularly important as new understanding of conditions like psoriasis and atopic dermatitis evolve and new treatmNew Topical Options for Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-topical-options-for-psoriasis/19979/Leon Kircik, MD shares his excitement about new molecules for psoriasis. He discusses the available data for tapinarof, a first-in-class small-molecule topical therapeutic aryl hydrocarbon receptor (AhR)–modulating agent, and roflumilast cream, a once-daily topical formulation of roflumilast, a highPediatric Derm: Sunscreen and Insect Repellent Safety
https://practicaldermatology.com/conferences/aad-summer-2021/pediatric-derm-sunscreen-and-insect-repellent-safety/19973/Parents of pediatric dermatology patients often have lots of questions when it comes to sunscreen safety, especially in light of recent headlines about recalls and absorption concerns. Mercedes Gonzalez, MD offers tips for answering these burning questions, including knowing how to discuss availableScientifically Speaking: Diagnosing and Treating Hair Loss, Part 1
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-diagnosing-and-treating-hair-loss-part-1/19954/Hair loss is distressing for many patients. The first step in management is to identify the cause of hair loss, modify contributing factors, and develop an effective treatment plan. Host Joel L. Cohen, MD discusses the challenges of managing hair loss with Marc Avram, MD, Cheryl Burgess, MD, and ReeStraight Scoop: Audience Questions Answered
https://practicaldermatology.com/topics/practice-management/straight-scoop-audience-questions-answered/19820/The panelists respond to questions from the audience about negotiating, choosing opportunities, and even how to say "No" the right way.Why social networking for your practice is more important than ever
https://practicaldermatology.com/topics/practice-management/why-social-networking-for-your-practice-is-more-important-than-ever/19811/In uncertain times, acquiring and retaining patients can be more difficult than ever. This Ekwa Marketing video discusses how social media can help you connect, communicate, and boost your professional reputation.Toxin Time: What’s New and Exciting with Neuromodulators
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/toxin-time-whats-new-and-exciting-with-neuromodulators/19768/Joel Cohen, MD takes a deep dive into the most recent data on neuromodulators including post-hoc analyses on the potential durability of response. Dr. Cohen also shares updates on Revance’s DAXI, Botox Cosmetic and liquid toxins under development by Galderma and Allergan.